Programme · resources
How catalytic capital could be used
Plain-language planning for NWPharmaTech’s CHR-P programme — a proposed Phase 2B study in people at clinical high risk for psychosis (CHR-P). This page is informational. It is not an offer to invest, a prospectus, or open subscription.
Last reviewed: 23 September 2026
What this page is
This page explains how a planning target of approximately US$10 million relates to the proposed Phase 2B CHR-P programme. You cannot invest, pay, subscribe, or connect a wallet on this website. This site does not accept investments.
On this website today: learn about the science, read the public synopsis, how the funding model works, and contact us about research or collaboration.
One programme
The public programme is the proposed Phase 2B working design (approximately 328 participants; four arms; about 12 weeks of treatment with further follow-up). Effectiveness in this population has not been established. Other research tracks, if any, are documented internally for diligence and are not part of this public summary.
What ~US$10M means
Approximately US$10 million is a planning target for catalytic programme funding for the proposed Phase 2B CHR-P programme.
- It is not money already raised
- It is not a validated vendor invoice or current CRO quote
- It is not a priced offer on this website
- It is not a claim that catalytic capital fully funds a complete Phase 2B trial
Planning objective through concrete activities
Illustrative. Subject to financing, approvals, and current cost discovery, catalytic capital at the planning-target scale could be directed toward activities such as:
| Cluster | Illustrative activities |
|---|---|
| Clinical preparation | Version-controlled synopsis path; ethics and regulatory readiness; operationalisation of eligibility and endpoints with the clinical team |
| Trial operations | CRO selection and start-up; monitoring and project management setup; data-management and PV plans |
| Product supply | IMP / CMC activities required for a start window; packaging / labelling path as applicable |
| Regulatory work | Filings and interactions required for start-up in applicable jurisdictions |
| Data analysis | Statistics and medical writing path as funded under the use-of-proceeds |
| Contingency | Holdback for wind-down, ethics close-out, and audit |
These are illustrative activity clusters, not a promise that every line is funded or that sites are contracted.
Next funded-milestone framing
Proposed · planning.
Catalytic preparation and start-up toward a proposed Phase 2B.
The remaining funding need to complete a full multiregional 328-participant run is to-be-established pending a current Phase 2B RFQ and Board use-of-proceeds. A current remaining funding figure is not published here pending a Phase 2B RFQ and Board use-of-proceeds.
How spend would be controlled
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
Raised capital, if any, would sit in a ring-fenced programme vehicle under bank / custody accounts with dual-control release against operational milestones — not efficacy claims. NWPharmaTech remains pharmaceutical sponsor. Details: How the funding model works.
What supporters would not get
- No NWPharmaTech parent equity in this mandate
- No ownership of the medicine, core IP, or patient data
- No medical / clinical voting
- No public retail token sale or DEX liquidity
- Following the programme as a community member is not an investment entitlement
Next steps for visitors
Learn about the science · read the public synopsis · read How the funding model works · contact us about research or collaboration. There is no Invest button on this website.
Research funding (conceptual)
Platform under evaluation · register-first fallback · not offering terms on this site · production investment, payment and token issuance remain inactive.